Renata Ferrarotto, John M. Kaczmar, David R. Spigel, Christine H. Chung, Dan Paul Zandberg, Irene Braña, Caroline Even, Kevin Joseph Harrington, Lisa F. Licitra, Bhumsuk Keam, Danny Rischin, Rita P. Dalal, David Raben, Rachel Salazar, Jeltje Schulten, Glenn J. Hanna. "A multicenter, randomized, double-blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: The FORTIFI-HN01 study.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.tps6113